Egetis Therapeutics Crecimiento futuro

Future controles de criterios 6/6

Se prevé un crecimiento anual de los beneficios y los ingresos de Egetis Therapeutics de 106.4% y 81.7% por año respectivamente. Se prevé que el BPA crezca en un 108% al año. Se espera que la rentabilidad financiera sea de 26.6% en 3 años.

Información clave

106.4%

Tasa de crecimiento de los beneficios

108.0%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs	45.7%
Tasa de crecimiento de los ingresos	81.7%
Rentabilidad financiera futura	26.6%
Cobertura de analistas	Low
Última actualización	15 Nov 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Is Egetis Therapeutics (STO:EGTX) Using Debt Sensibly?

Aug 20

Here's Why We're Not Too Worried About Egetis Therapeutics' (STO:EGTX) Cash Burn Situation

May 26

Egetis Therapeutics AB (publ) (STO:EGTX) Is Expected To Breakeven In The Near Future

Mar 22

Previsiones de crecimiento de beneficios e ingresos

OM:EGTX - Estimaciones futuras de los analistas y datos financieros pasados (SEK Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	456	93	332	189	5
12/31/2025	325	-3	-141	-41	5
12/31/2024	54	-323	-334	-275	3
9/30/2024	68	-319	-216	-216	N/A
6/30/2024	71	-319	-247	-247	N/A
3/31/2024	63	-327	-254	-254	N/A
12/31/2023	58	-327	-278	-278	N/A
9/30/2023	31	-319	-299	-299	N/A
6/30/2023	24	-286	-249	-249	N/A
3/31/2023	22	-240	-220	-220	N/A
12/31/2022	23	-194	-173	-173	N/A
9/30/2022	20	-148	-137	-137	N/A
6/30/2022	21	-113	-125	-125	N/A
3/31/2022	42	-114	-128	-128	N/A
12/31/2021	38	-104	-130	-130	N/A
9/30/2021	40	-147	-143	-143	N/A
6/30/2021	36	-153	-137	-137	N/A
3/31/2021	33	-155	-133	-133	N/A
12/31/2020	41	-178	-135	-135	N/A
9/30/2020	53	-127	-124	-124	N/A
6/30/2020	56	-134	-134	-134	N/A
3/31/2020	39	-127	-127	-127	N/A
12/31/2019	83	-61	-63	-63	N/A
9/30/2019	77	-61	-54	-54	N/A
6/30/2019	77	-48	-38	-38	N/A
3/31/2019	82	-46	-39	-39	N/A
12/31/2018	28	-85	-81	-81	N/A
9/30/2018	31	-95	-106	-106	N/A
6/30/2018	24	-103	N/A	-97	N/A
3/31/2018	14	-91	N/A	-90	N/A
12/31/2017	14	-88	N/A	-87	N/A
9/30/2017	N/A	-67	N/A	-51	N/A
6/30/2017	0	-48	N/A	-49	N/A
3/31/2017	N/A	-44	N/A	-41	N/A
12/31/2016	N/A	-38	N/A	-36	N/A
9/30/2016	N/A	-36	N/A	-36	N/A
6/30/2016	N/A	-39	N/A	-38	N/A
3/31/2016	N/A	-39	N/A	-44	N/A
12/31/2015	N/A	-44	N/A	-51	N/A
9/30/2015	N/A	-53	N/A	-55	N/A
6/30/2015	N/A	-53	N/A	-52	N/A
3/31/2015	N/A	-54	N/A	-47	N/A
12/31/2014	N/A	-48	N/A	-41	N/A
9/30/2014	N/A	-38	N/A	-34	N/A
6/30/2014	N/A	-31	N/A	-31	N/A
3/31/2014	N/A	-24	N/A	-25	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que EGTX sea rentable en los próximos 3 años, lo que se considera un crecimiento más rápido que la tasa de ahorro (1.2%).

Beneficios vs. Mercado: Se prevé que EGTX sea rentable en los próximos 3 años, lo que se considera un crecimiento del mercado superior a la media.

Beneficios de alto crecimiento: Se espera que EGTX sea rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (81.7% al año) de EGTX crezcan más rápidamente que los del mercado Swedish (0% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos (81.7% al año) de EGTX crezcan más rápidamente que un 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Se prevé que la rentabilidad financiera de EGTX sea alta dentro de 3 años (26.6%)

Egetis Therapeutics Crecimiento futuro

Future controles de criterios 6/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Consensus EPS estimates upgraded to kr0.81 loss, revenue downgraded

Forecast breakeven date moved forward to 2025

Consensus revenue estimates increase by 21%

Price target decreased by 17% to kr11.90

Consensus revenue estimates increase by 13%

Recent updates

Consensus EPS estimates upgraded to kr0.81 loss, revenue downgraded

Forecast breakeven date moved forward to 2025

Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Egetis Therapeutics AB (publ), Annual General Meeting, May 06, 2025

New minor risk - Shareholder dilution

Egetis Therapeutics AB (Publ) Announces Resignation of Peder Walberg from the Board of Directors

Egetis Submits A Patent Application to the United States Patent and Trademark Office for Processes of Preparation of Tiratricol

Consensus revenue estimates increase by 21%

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Price target decreased by 17% to kr11.90

Egetis Therapeutics AB (publ) to Report Fiscal Year 2024 Results on Feb 26, 2025

Is Egetis Therapeutics (STO:EGTX) Using Debt Sensibly?

Consensus revenue estimates increase by 13%

Egetis Therapeutics AB (publ) Announces Topline Results of the Phase 2 Triac Trial II with Emcitate (Tiratricol) for MCT8 Deficiency

Consensus revenue estimates decrease by 14%, EPS upgraded

Consensus EPS estimates upgraded to kr0.83 loss, revenue downgraded

Consensus revenue estimates increase by 25%

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

New major risk - Financial position

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Egetis Therapeutics AB (publ) to Report First Half, 2024 Results on Aug 22, 2024

New minor risk - Share price stability

Price target increased by 11% to kr12.30

Egetis Therapeutics AB (publ) Provides Update on Disease Awareness and the Expanded Access Program for Tiratricol (Emcitate) in the USA

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Egetis Therapeutics AB (publ) to Report Q1, 2024 Results on May 03, 2024

Egetis Therapeutics AB (publ), Annual General Meeting, May 06, 2024

Egetis Therapeutics AB (publ) Announces Ema Validation of Marketing Authorisation Application for Emcitate for the Treatment of Mct8 Deficiency

Egetis Therapeutics AB (publ) Submits Marketing Authorisation Application for Emcitate for Treatment of MCT8 Deficiency to the European Medicines Agency

Egetis Therapeutics AB (publ) to Report Fiscal Year 2023 Results on Feb 24, 2024

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Egetis Therapeutics AB (Publ) Announces First Patient Included and Second Site Activated in the Pivotal Retriact Trial

Chief Executive Officer recently bought kr61k worth of stock

Price target decreased by 8.3% to kr13.30

Forecast breakeven date pushed back to 2025

Independent Director recently bought kr206k worth of stock

Director recently bought kr992k worth of stock

Consensus revenue estimates decrease by 14%, EPS upgraded

Price target decreased by 7.4% to kr14.50

Here's Why We're Not Too Worried About Egetis Therapeutics' (STO:EGTX) Cash Burn Situation

Egetis Terminates Discussions Regarding Potential Acquisition

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Price target increased by 13% to kr17.75

Forecast breakeven date pushed back to 2025

Consensus revenue estimates fall by 16%

Full year 2022 earnings released: kr1.00 loss per share (vs kr0.63 loss in FY 2021)

Egetis Therapeutics AB (Publ) Appoints Katayoun Welin-Berger as Vice President Operations, Effective from March 2023

Egetis Therapeutics AB (publ), Annual General Meeting, Apr 27, 2023

Consensus EPS estimates fall by 15%

We're Keeping An Eye On Egetis Therapeutics' (STO:EGTX) Cash Burn Rate

Egetis Therapeutics AB Submits Expanded Access Program for Emcitate® in the USA

Egetis Therapeutics AB (publ) to Report Fiscal Year 2022 Results on Feb 22, 2023

Less than half of directors are independent

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Consensus forecasts updated

Egetis Therapeutics AB (publ) Receives Positive Opinion on Orphan Designation for Aladote® from the European Medicines Agency for the Prevention of Acute Liver Failure

Forecast breakeven date pushed back to 2024

Egetis Therapeutics AB (Publ) Appoints Sara Melton as President of North America

Egetis Therapeutics AB (Publ) Appoints Sara Melton as President of North America

Will Egetis Therapeutics (STO:EGTX) Spend Its Cash Wisely?

No longer forecast to breakeven

Egetis Therapeutics AB (Publ) Announces Executive Changes

Price target decreased to kr9.00

Less than half of directors are independent

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Egetis Therapeutics AB (Publ) Announces That the Recruitment Target Has Been Met in the Emcitate® Triac Trial II Study

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Egetis Therapeutics AB (publ) Secures Conditional Acceptance for Emcitate® as Brand Name in the US